Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 200 participants.

Also called NCT05850091

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05850091
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05850091. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-07 (actual); primary completion 2027-06-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
Acronym
PROACT 2
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Colchicine
Intervention (Drug)
Placebo
Lead sponsor
Massachusetts General Hospital (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct05850091
Content hash
db7e6ddc0abbf49809cc119bf56820500928b2cce4f0733bcfdaf54930b1c93c